Other News To Note
Friday, June 3, 2011
Opexa Therapeutics Inc., of The Woodlands, Texas, met with Health Canada's Biologics and Genetics Therapies Directorate to review the status of its cellular therapy for multiple sclerosis, Tovaxin. The company received guidance from the agency regarding its plan to carry out Phase III trials at some Canadian sites. A positive review is required before it can initiate a clinical study.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.